《大行报告》富瑞下调三生制药(01530.HK)目标价至9元 评级“持有”

阿斯达克财经
Jan 18, 2023

富瑞发表研究报告指,三生制药(01530.HK) 的核心产品特比澳(TPIAO)获中国工信部审核,用于治疗在儿童或青少年的慢性原发性免疫性血小板减少症(ITP),数据显示产品三期临床研究已达到预设有效率主要终点,见效快并具良好安全性。该行表示,特比澳用于治疗成人ITP及化疗引起的血小板减少症(CIT)早于2006年上市,产品自2018至2021年的销售额复合年增长率为23%,占三生制药2021年...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10